
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is an emerging biotech company with a strong management team that has shown potential in developing obefazimod for the treatment of ulcerative colitis and other IBDs. With a Buy rating and a target price of $140, the stock is expected to perform well due to the high unmet need for treatments in the IBD market and potential partnerships and acquisitions. Investors should closely monitor the progress of the Phase 2 trial and any updates on the drug's potential approval and market launch.
Bears say
Abivax is facing stiff competition in the market for inflammatory bowel disease treatments, with potential downsides in the case of failed acquisition or safety concerns. While the company has a strong management team and enough cash to continue operations for a certain period of time, concerns about the efficacy and potential for acquisition of its drug obefazimod may limit its success in the long term. Its potential in a growing market is also hindered by competition from biosimilars and new treatments, as well as the presence of other highly valued pharmaceutical and biotechnology companies in the market.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares